Invivoscribe® offers a full range of hematology-oncology testing products (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software). Products include the FDA-approved, CE-marked and MHLW/PMDA approved CDx LeukoStrat® FLT3 Mutation Assay, RUO and CE-marked assays for capillary and NGS platforms. We operate a global network of clinical reference labs in USA, Europe and Japan, offering internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatment, and development of companion diagnostics.